| 臺大學術典藏 |
2020-11-27T08:14:34Z |
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma
|
Huang S.-P.;Wu M.-S.;Shun C.-T.;Wang H.-P.;Chang-Yao Hsieh;Kuo M.-L.;Lin J.-T.; Huang S.-P.; Wu M.-S.; Shun C.-T.; Wang H.-P.; CHANG-YAO HSIEH; Kuo M.-L.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-27T03:28:42Z |
Gastrointestinal: Dissecting esophageal hematoma with a Mallory-Weiss tear
|
CHIEH-CHANG CHEN; Yang C.-Y.; Wang H.-P.; Lin J.-T.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:42Z |
Lateral abdominal wall hematoma due to tear of internal abdominal oblique muscle in a patient under warfarin therapy
|
Tai C.-M.; Liu K.-L.; CHIEH-CHANG CHEN; Lin J.-T.; Wang H.-P. |
| 臺大學術典藏 |
2020-11-27T03:28:41Z |
Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chen M.-J.; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Sheng W.-H.; Wang H.-P.; Wu M.-S.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-27T03:28:40Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chien-Chuan Chen; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; Wang C.-H.; Kuo S.-H.; Wu C.-Y. |
| 臺大學術典藏 |
2020-11-27T03:28:40Z |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chen M.-J.; Chien-Chuan Chen; Chang C.-Y.; Fang Y.-J.; Lee J.-Y.; Hsu S.-J.; Luo J.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Wang H.-P.; Yang U.-C.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection
|
Chen M.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Lee Y.-C.; Chang C.-Y.; Wu J.-Y.; Bair M.-J.; Lin J.-T.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria
|
Fang Y.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Lee J.-Y.; Hsu Y.-C.; Chen M.-J.; Tseng P.-H.; Chien-Chuan Chen; Chang C.-Y.; Yang T.-H.; Chang W.-H.; Wu J.-Y.; Wang H.-P.; Luo J.-C.; Lin J.-T.; Shun C.-T.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:39Z |
The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors - A nationwide study
|
Liou J.-M.; Chang C.-Y.; Chen M.-J.; CHIEH-CHANG CHEN; Fang Y.-J.; Lee J.-Y.; Wu J.-Y.; Luo J.-C.; Liou T.-C.; Chang W.-H.; Tseng C.-H.; Wu C.-Y.; Yang T.-H.; Chang C.-C.; Wang H.-P.; Sheu B.-S.; Lin J.-T.; Bair M.-J.; Wu M.-S.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Lee Y.-C.; Wang Y.-C.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial
|
Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Tsao F.-Y.; Liu T.-Y.; Hsieh C.-F.; Bair M.-J.; Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-Y.; Chen M.-J.; Chien-Chuan Chen; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C. |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen–Negative Patients
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Kao J.-H.; Wang W.-L.; Yang T.-H.; Wang C.-S.; Chiang M.-F.; CHIEH-CHANG CHEN; Fang Y.-J.; Hung H.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-27T03:28:38Z |
Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of helicobacter pylori: A randomized trial
|
Liou J.-M.; Bair M.-J.; CHIEH-CHANG CHEN; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Chang W.-H.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hung H.-W.; Lin J.-T.; Chang C.-Y.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-27T03:28:37Z |
Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy
|
Hsu Y.-C.; Mo L.-R.; Chang C.-Y.; Wu M.-S.; Yang T.-H.; Kao J.-H.; CHIEH-CHANG CHEN; Tseng C.-H.; Tai C.-M.; Lin C.-W.; Wu C.-Y.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-27T03:28:37Z |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
|
Liou J.-M.; Fang Y.-J.; CHIEH-CHANG CHEN; Bair M.-J.; Chang C.-Y.; Lee Y.-C.; Chen M.-J.; Chien-Chuan Chen; Tseng C.-H.; Hsu Y.-C.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chang C.-C.; Chen C.-Y.; Chen P.-Y.; Shun C.-T.; Hsu W.-F.; Hu W.-H.; Chen Y.-N.; Sheu B.-S.; Lin J.-T.; Wu J.-Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
14 Day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: A multicentre, non-inferiority, randomized trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Fang Y.-J.; Chen P.-Y.; Chang C.-Y.; Chou C.-K.; Chen M.-J.; Tseng C.-H.; Lee J.-Y.; Yang T.-H.; Chiu M.-C.; Yu J.-J.; Kuo C.-C.; Luo J.-C.; Hsu W.-F.; Hu W.-H.; Tsai M.-H.; Lin J.-T.; Shun C.-T.; Twu G.; Lee Y.-C.; Bair M.-J.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:36Z |
Impact of amoxicillin resistance on the efficacy of amoxicillincontaining regimens for Helicobacter pylori eradication: Analysis of five randomized trials
|
Chen M.-J.; Wu M.-S.; Chien-Chuan Chen; CHIEH-CHANG CHEN; Fang Y.-J.; Bair M.-J.; Chang C.-Y.; Lee J.-Y.; Hsu W.-F.; Luo J.-C.; Lin J.-T.; Liou J.-M.; on behalf of the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHIEH-CHANG CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; Chun-Chao Chang; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Wu M.-S.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk
|
Hsu Y.-C.; Nguyen M.H.; Mo L.-R.; Wu M.-S.; Yang T.-H.; CHIEH-CHANG CHEN; Tseng C.-H.; Tai C.-M.; Wu C.-Y.; Lin J.-T.; Tanaka Y.; Chang C.-Y. |
| 臺大學術典藏 |
2020-11-27T03:28:35Z |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection
|
Chen M.-J.; Chien-Chuan Chen; Chen Y.-N.; CHIEH-CHANG CHEN; Fang Y.-J.; Lin J.-T.; Wu M.-S.; Liou J.-M.; for the Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:33Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou J.-M.; CHIEH-CHANG CHEN; Chang C.-M.; Fang Y.-J.; Bair M.-J.; Chen P.-Y.; Chang C.-Y.; Hsu Y.-C.; Chen M.-J.; Chien-Chuan Chen; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Chen C.-Y.; Hsu W.-F.; Chen Y.-N.; Wu J.-Y.; Lin J.-T.; Lu T.-P.; Chuang E.Y.; El-Omar E.M.; Wu M.-S.; Taiwan Gastrointestinal Disease; Helicobacter Consortium |
| 臺大學術典藏 |
2020-11-27T03:28:31Z |
Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus
|
Liou J.-M.; Malfertheiner P.; Lee Y.-C.; Sheu B.-S.; Sugano K.; Cheng H.-C.; Yeoh K.-G.; Hsu P.-I.; Goh K.-L.; Mahachai V.; Gotoda T.; Chang W.-L.; Chen M.-J.; Chiang T.-H.; CHIEH-CHANG CHEN; Wu C.-Y.; Leow A.H.-R.; Wu J.-Y.; Wu D.-C.; Hong T.-C.; Lu H.; Yamaoka Y.; Megraud F.; Chan F.K.L.; Sung J.J.Y.; Lin J.-T.; Graham D.Y.; Wu M.-S.; El-Omar E.M. |
| 臺大學術典藏 |
2020-11-19T12:50:07Z |
Comparison between resectable gastric adenocarcinomas seropositive and seronegative for Helicobacter pylori
|
Lee, W J;Lin, J T;Shun, C T;Wen-Chung Lee;Yu, S C;Lee, P H;Chang, K J;Wei, T C;Chen, K M; Lee, W J; Lin, J T; Shun, C T; WEN-CHUNG LEE; Yu, S C; Lee, P H; Chang, K J; Wei, T C; Chen, K M |
| 臺大學術典藏 |
2020-11-19T08:19:39Z |
Overexpression of p53 in different subtypes of intestinal metaplasia and gastric cancer
|
Wu M.-S.;Shun C.-T.;Wen-Chung Lee;Chen C.-J.;Wang H.-P.;Lee W.-J.;Sheu J.-C.;Lin J.-T.; Wu M.-S.; Shun C.-T.; WEN-CHUNG LEE; Chen C.-J.; Wang H.-P.; Lee W.-J.; Sheu J.-C.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-19T08:19:31Z |
Helicobacter pylori infection and age on the development of intestinal metaplasia - A multiple logistic regression analysis
|
Wang C.-C.;Wu M.-S.;Wang H.-H.;Wang H.-P.;Wen-Chung Lee;Shun C.-T.;Lin J.-T.; Wang C.-C.; Wu M.-S.; Wang H.-H.; Wang H.-P.; WEN-CHUNG LEE; Shun C.-T.; Lin J.-T. |
| 臺大學術典藏 |
2020-11-19T08:19:23Z |
Diagnosis of gastric adenocarcinoma using a scoring system: Combined assay of serological markers of Helicobacter pylori infection, pepsinogen I and gastrin
|
Lin J.-T.;Wen-Chung Lee;Wu M.-S.;Wang J.-T.;Wang T.-H.;Chen C.-J.; Lin J.-T.; WEN-CHUNG LEE; Wu M.-S.; Wang J.-T.; Wang T.-H.; Chen C.-J. |
